Latest From NsGene AS
Deals and R&D partnerships are coming thick and fast for Takeda in the first few days of the year, with the major Japanese firm unveiling a new tie-up with NsGene to progress direct-delivered cell therapies for Parkinson's disease.
Biogen Idec has agreed to pay $200m up front and up to $475m in milestones to acquire the UK developer of drugs for neuropathic pain Convergence Pharmaceuticals. The target company's most promising pipeline drug is CNV1014802, which has yielded positive Phase II results for trigeminal neuralgia (TGN), an orphan condition characterized by excruciating face pain.
A safety review of the first three Alzheimer's disease patients given NsGene's nerve-growth-factor secreting encapsulated cells has been favourable, and a further three patients have now be included in the Phase Ib clinical trial.
- Gene Therapy, Cell Therapy
- Large Molecule
- Medical Devices
- Site Specific
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- NsGene AS
- Senior Management
Teit E Johansen, PhD, Pres. & CEO
Lars U Wahlberg, MD, PhD, EVP, COO
- Contact Info
Phone: (45) 4460 8900
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.